eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
1/2021
vol. 7
 
Share:
Send email
Share:
abstract:
Original paper

Predictors of azathioprine toxicity in children with autoimmune hepatitis

Behairy El-Sayed Behairy
1
,
Hala Hany El-Said
2
,
Hatem Abd-Alsattar Konswa
1
,
Ahmed El-Sayed Nour El-Deen
3
,
Nermin Mohamed Adawy
1
,
Ahmad Mohamed Sira
1

  1. Department of Pediatric Hepatology, Gastroenterology, and Nutrition, National Liver Institute, Menoufia University, Egypt
  2. Department of Clinical Biochemistry, National Liver Institute, Menoufia University, Egypt
  3. Department of Physiology, Faculty of Medicine, Al-Azhar University, Assuit, Egypt
Clin Exp HEPATOL 2021; 7, 1: 47-54
DOI: https://doi.org/10.5114/ceh.2021.104634
Online publish date: 2021/03/25
View full text Get citation
 
PlumX metrics:
Aim of the study
Azathioprine (AZA) is an important steroid-sparing drug in the management of autoimmune hepatitis (AIH). Avoidance of its adverse events that could be severe and carry a risk of mortality in a few cases is important, preferably with cheap and easy assessments that could be feasible in developing countries with the unavailability of molecular assays. Assessment of thiopurine methyltransferase (TPMT), the key enzyme for the inactivation of AZA, as a predictor of AZA toxicity had been a matter of conflict. This work aimed to study the role of TPMT serum level assessment and other host-, disease-, and treatment-related factors in predicting AZA toxicity.

Material and methods
Sixty-six children with AIH, divided into two groups, were recruited. Group 1 included twelve children with AZA toxicity and group 2 included fifty-four children without AZA toxicities. Both groups were compared for demographic, clinical, laboratory, histopathological, and treatment-related factors, and serum TPMT level, measured by ELISA.

Results
TPMT serum level was comparable in both groups (p = 0.363). Duration of treatment until enzyme normalization and duration of AZA therapy were significantly associated with AZA toxicity (p = 0.007 and p = 0.01, respectively). At the first follow-up treatment with AZA, total leucocyte count (TLC) and neutrophil counts were significantly lower in group 1 (p = 0.005 and p = 0.002, respectively). Moreover, the percentage reduction of TLC and neutrophil counts were significantly higher in group 1 (p < 0.001, for both).

Conclusions
Monitoring for AZA adverse events in those with the defined predictors of AZA-related adverse events is more important than TPMT assessment.

keywords:

autoimmune hepatitis, adverse events, azathioprine, myelosuppression, thiopurine methyltrans­ferase
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.